Science Corporation, the brain-interface company founded by former Neuralink president Max Hodak, has raised a $400 million Series D. Investors valued it at $3.5 billion, TechCrunch reported, citing a person familiar with the deal. Science’s own announcement does not give a valuation.
Our number: Science says the round brings its total raised since 2021 to more than $900 million, so its earlier rounds came to more than $500 million and the Series D is less than 45% of the total, by our arithmetic.
Business Pill · Lead Time Explained
An evergreen Business Engineer explainer on lead time. It teaches the general idea only and does not discuss Science Corporation.
The key insight: Science Corporation raised a $400 million Series D, valued at $3.5 billion according to TechCrunch’s source, and says it has raised more than $900 million since 2021; the new round is less than 45% of that total, by our arithmetic.
What Science Announced
Science says the round had “participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech, among others”. It says the round comes a few months after the European commercial launch of PRIMA.
Science describes PRIMA as “the first brain-computer interface to be CE marked to restore form vision”, the ability to read letters, numbers and words, for patients blinded by certain types of late-stage macular degeneration. TechCrunch reports that the device is available in Germany.
Science says it will “prepare for its launch in the United States, where we’re pursuing FDA approval through the Humanitarian Device Exemption pathway”. TechCrunch reports that Hodak said on stage at a TechCrunch event that PRIMA is now being trialled for Stargardt disease, another cause of blindness.

The Bigger Bet
Science also says it will “make substantial further investments in our biohybrid program, a neural interface that integrates engineered neurons with the brain’s own circuits”. TechCrunch reports that the company is designing initial human trials of that device with Yale neurosurgery professor Murat Günel.
The round landed on the same day as two other large deep-tech raises we covered: Genesis AI’s $500 million at $3.5 billion and Isomorphic Labs’ $5 billion.
The Structural Read
As we read the announcement, Science is funding two businesses at once: a CE-marked retinal implant it says it will take to the US, and a biohybrid neural interface it says it will keep investing in.
As we read TechCrunch’s report, the valuation rests on an approved product in Europe: TechCrunch says PRIMA is approved in Europe and available in Germany.
Science Corporation, Series D announcement
“We’ll use the new capital to accelerate PRIMA’s availability across Europe and to prepare for its launch in the United States”
Three Implications
FOR PATIENTS Science says PRIMA is CE marked to restore form vision for patients blinded by certain types of late-stage macular degeneration.
FOR US REGULATORS Science says it is pursuing FDA approval through the Humanitarian Device Exemption pathway.
FOR INVESTORS Science lists Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech among the round’s participants.
What Is Not Established
The $3.5 billion valuation is from TechCrunch’s source; Science does not state it. Science does not give PRIMA’s price, the number of patients treated, revenue or the lead investor.
The FDA has not approved PRIMA; Science says it is pursuing approval. We did not contact Science Corporation.
The Bottom Line
Science Corporation raised $400 million, at $3.5 billion according to TechCrunch’s source, and says it has raised more than $900 million since 2021. The Series D is less than 45% of that total, by our arithmetic.
97,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.
A note on sourcing. The round, investors, total raised, PRIMA’s CE marking and the US plans are from Science Corporation’s own announcement of 17 November 2026, read in full. The $3.5 billion valuation, PRIMA’s availability in Germany, the Stargardt trial and the Yale trial design are as reported by TechCrunch. The share of the total is our arithmetic. We did not contact Science Corporation.
Sources: Science Corporation, Series D, 17 Nov 2026 · TechCrunch, 17 Nov 2026









